Celyad Oncology Company Description

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer.

The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies.

It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets.

The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Celyad Oncology SA

Country	Belgium
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	19
CEO	Matthew Kane

Contact Details

Address: Axis Business Park Mont-Saint-Guibert, 1435 Belgium
Phone	32 1 039 41 00
Website	celyad.com

Stock Details

Ticker Symbol	CYAD
Exchange	Euronext Brussels
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	BE0974260896
SIC Code	2836

Key Executives

Name	Position
Matthew R. Kane	Chief Executive Officer
Michel E. J. Lussier BME, M.B.A., M.S., MS BME	Co-Founder and Executive Director
David Georges	Vice President of Finance and Administration
Sara Zelkovic	Communications and Investor Relations Director
An Phan	Head of Legal
Hannes Iserentant	Head of Intellectual Property
Eytan Breman	Head of Research & Development
Philippe Dechamps	Corporate Secretary